Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06833008 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

A Phase 1 study of Advanced Solid Tumor, sponsored by Ipsen.

Recruiting
Registry status
Phase 1
Development phase
85
Enrollment target
13
Study locations

NCT06833008 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Ipsen. The registered enrollment target is 85 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (56% lower). The trial reports 13 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06833008, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Ipsen.

RECRUITING
Registry status
Phase 1
Development phase
85 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG IPN01195

Study Locations (13)

Other

  • Centre Léon Bérard - Lyon - Lyon
  • Paris Saint-Louis - Paris
  • IGR-Villejuif - Villejuif
  • Istituto Nazionale dei Tumori - Milan
  • Istituto Nazionale Tumori IRCCS - Fondazione Pascale - Naples
  • Val D'Hebron - Barcelona
  • Hospital Universitario Quirónsalud Madrid - Madrid
  • M.D. Anderson Center Madrid - Madrid

Michigan

  • START Mid-West - Grand Rapids

Tennessee

  • Sarah Cannon Research Institute (SCRI) - Nashville - Nashville

Texas

  • Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas - Dallas

Utah

  • START Mountan Region - West Valley City

Virginia

  • Virginia Cancer Specialist- Fairfax - Fairfax

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2025-03-14
Est. Completion 2028-10-03
Phase Phase 1

Sponsor

Ipsen

85 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06833008

The ClinicalTrials.gov registry entry for NCT06833008 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (56% lower). The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which IPN01195 is the first listed.

NCT06833008 reports 13 study locations spanning 6 distinct geographic areas - top geographies include Other, Michigan, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06833008 about?

NCT06833008 is a clinical study titled "A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours". The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places...

What is the current status of trial NCT06833008?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2025-03-14. Estimated completion is 2028-10-03.

What conditions does trial NCT06833008 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06833008?

The interventions under investigation include: IPN01195 (DRUG).

Who is sponsoring clinical trial NCT06833008?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06833008 being conducted?

This trial has 13 study locations across Michigan, Tennessee, Texas, Utah, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.